+

WO1997048405A1 - Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes - Google Patents

Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes Download PDF

Info

Publication number
WO1997048405A1
WO1997048405A1 PCT/RU1996/000168 RU9600168W WO9748405A1 WO 1997048405 A1 WO1997048405 A1 WO 1997048405A1 RU 9600168 W RU9600168 W RU 9600168W WO 9748405 A1 WO9748405 A1 WO 9748405A1
Authority
WO
WIPO (PCT)
Prior art keywords
placental
product
mass
mixed
basis
Prior art date
Application number
PCT/RU1996/000168
Other languages
English (en)
Russian (ru)
Inventor
Jury Evgenievich Belyaev
Original Assignee
Jury Evgenievich Belyaev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jury Evgenievich Belyaev filed Critical Jury Evgenievich Belyaev
Priority to PCT/RU1996/000168 priority Critical patent/WO1997048405A1/fr
Priority to AU70030/96A priority patent/AU7003096A/en
Publication of WO1997048405A1 publication Critical patent/WO1997048405A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells

Definitions

  • the remaining inventions relate to medicine. but by name. ⁇ therapy and can serve. with one side. the original material for the receipt of different types of different medicinal products and the use of many medicinal products. for example. affect the t-channel exchange. and on the other hand - for the immediate treatment of inflammation of various causes. ⁇ automatic complications. ⁇ ana ⁇ . burn. skin diseases and
  • the inventions may be used in veterinary medicine for the treatment of lively various diseases. and may also be used as a method. for example. for massage with biologically active substances. and may also be used as a primary medical treatment product 2 0 for external use.
  • the product is known. good placental material.
  • the base of the medicinal product is known. Obtained from the previously indicated product. A quick part contains crushed and broken parts in the process of processing from a placental material. (see also) a physiological solution of a chlorine natrium in the 10th volume. This is why the suspension has been released. Filtered
  • the source material of the indicated product is found to be unprotected on clean air. In this case, it is exchanged - it is small. It is not always indifferent to living in an organism. ⁇ . ⁇ .. just like. In hospital conditions, I accumulate all the strains that are harmful to the human organism. is it sta- v? ⁇ il ⁇ . structure and friends. that is always an advantage of the naive construction of the placenta material due to the merger of the activity of the microorganisms and activity in the end of the year.
  • a well-known base of medicinal product Obtained from 20 known industrial products. cannot be used as a ready-to-use material for the manufacture of medicinal products.
  • a well-known base contains the first parts of the shredded product from the placental material. non-biologically active substances in the active state. Otherwise, its particles have a well-developed development. This interferes with their interaction with a larger number of purposeful additions, and when you store the basics, they are caked, are closed due to their uncomfortable relations. and when introduced into the solution, it is liquid phase and is precipitated, disrupting the equilibrium of active substances in the medicinal product. ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • Izves ⁇ n ⁇ e le ⁇ a ⁇ s ⁇ venn ⁇ e s ⁇ eds ⁇ v ⁇ on e ⁇ y izves ⁇ n ⁇ y ⁇ sn ⁇ ve impossible is ⁇ lz ⁇ va ⁇ in ⁇ aches ⁇ ve lechebn ⁇ g ⁇ s ⁇ eds ⁇ va na ⁇ uzhn ⁇ yu ⁇ i- Menenius ⁇ a ⁇ due ⁇ e ⁇ i ma ⁇ e ⁇ ial ⁇ m its ⁇ ve ⁇ dy ⁇ chas ⁇ its sv ⁇ eg ⁇ na ⁇ ivn ⁇ g ⁇ s ⁇ s ⁇ yaniya in ⁇ tsesse ⁇ ig ⁇ vleniya s ⁇ eds ⁇ va. ya ⁇ - 5 me ⁇ . at the same time as the sterilization of the plant. and because of the presence of solid particles. Shortfalls in falling to the rupture of the left skin cause strong painful sensations in the patient.
  • Dimethyl sulfide is known (synonyms: dimexide. ⁇ . ⁇ ! _Y). How to liquid the properties of a solvent and a conservative. as well as) as a medicinal product. They are using and treating patients. tie orders. volcanic flows. foreign medicine and so on ( ⁇ ashkovsky Nat. D .. "Medicinal products " . A benefit for the physician. Edition 1 0. Med. 1 March 2, 1985 .. Mentioned in the quality of external means.
  • the base of the medicinal product is known. Obtained from this well-known manufacturer. It contains solid particles of placenta from the placental material. Obtained after a young land user (see also).
  • Known medicinal product for example. affecting ⁇ cash exchange. containing the base in the form of solid particles from the ground floor (
  • This component is based on a particulate material in the form of particles of an inexpensively cultivated product in the base of the placenta. and in the quality of the target supplement - the historical disagreement of the Chloride.
  • the components are mixed, the suspension obtained is diluted in ampoules and sterilized at a temperature of + 120 C for ⁇ 5 hours. Before using the ampoule, it is intriguing. so that the particles of the known basic elements are equally divided in the factory.
  • biogenic stimulants It is indicated as an injection in a dose of 2 ml (a preliminary dose of 0.5% solution of novocaine) 1 time in 7-10 days: for a powder of 3 to 4 injections. You must return after 2 to 3 months.
  • the first objective of the present invention is the creation of 25 user solutions for receiving basic medical devices. existing material in such a state or with such a structure. koperato have deliberately provided ⁇ a to him the contents of a large number of ⁇ iological active substances. and also an agreement with many components. used for the receipt of various basic medicinal products. Otherwise, it would take a long time to take. Be transformed and processed without the need for biologically active substances.
  • the main task of the present invention is the creation of basic medicinal products from a well-known medical device. 35 existing conditions. and their material and structure. shortfalls would ensure the maintenance of a large number of biologically active substances and an agreement with various earmarked funds for the distribution of funds on a voluntary basis. ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the third objective of the present invention is the creation of 5 medicinal products on the previously indicated bases. existing community. and their material structure. and target benefits. high medication and internal or external use for the treatment of various diseases. including: psychosis. osteostochiasis. diseases of the engine and motor.
  • the first problem is solved by which is well known in the art for receiving the base of a medicinal product. containing a placenta material. according to the present invention.
  • the placenta material is in a native state.
  • the placental material is mixed with packaging. his good living condition. for example. with glycerol. and married. by the way, the quantity of glycerin makes up for the percentage of the mass of the viable material;
  • glycerin is usually up to 3% of the weight of the raw material and the material is used for freezing. ⁇ .e Take care of the internal facilities. Thereby, the initial positive state of the placental material.
  • the second task is solved by the fact that, in the well-known basis, which contains the semi-finished product from the placental material. according to the present invention. as part of the product, an amnesty-wrapped file is used. isolated from smart material. located in a native state. Constructed by 0.5 molar solution of sodium chloride. ingested with glycerol and frozen. ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the crushed semiproduct has a placental material. mixed with dimethyl sulfoxide in quantity and condition.
  • the liquid mass is in mixed form with a / or yellow mixture
  • ⁇ for the sake of basics, it looks like jelly.
  • the property and the mechanism of its development are similar to the above.
  • the main source of activity is high biological activity due to the stable composition of the material. rich biological active substances and long enjoy the unique properties of the placental material.
  • v ⁇ e ⁇ vye for izg ⁇ vleniya le ⁇ a ⁇ s ⁇ venny ⁇ s ⁇ eds ⁇ v on ⁇ sn ⁇ ve ⁇ latsen ⁇ a ⁇ n ⁇ g ⁇ ma ⁇ e ⁇ iala m ⁇ zhn ⁇ is ⁇ lz ⁇ va ⁇ ⁇ dn ⁇ v ⁇ emenn ⁇ or ⁇ ⁇ deln ⁇ s ⁇ i ⁇ m ⁇ nen ⁇ y lechebny ⁇ ⁇ e ⁇ a ⁇ a- ⁇ v as tselevy ⁇ d ⁇ bav ⁇ ⁇ e ⁇ ⁇ iziches ⁇ i ⁇ s ⁇ s ⁇ yany: zhid ⁇ s ⁇ i. a good deal of gas and gas.
  • This basic medicinal product is distinguished by the fact that it is known as 5 other basic principles by other version of the particles of grinded material. well-defined rivals. ⁇ less ms ⁇ certify. on the part of the part and the structure of its material. ⁇ réelle one day. famous medicinal products are known. Particles have a built-in structure. in particular. this is observed in vivo activated coal. being an adsorbent. ⁇ our case. exclusive property.
  • the material does not have a net structure. which, in turn, reduces the therapeutic effect of known substances.
  • the material is in the native state.
  • the third problem is solved by that. which is in the well-known medicinal product. containing the base of the crushed placental mother ⁇ mixed with her target supplement. ACCORDING TO THIS ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the liquid mass of the flat material is used in the framework of the base. It has a homogeneous structure and is in a mixed state. and its placental mother is in the native state. ⁇ itan in glycerin and ⁇ réelle ⁇ royal
  • the distinctive features are: the use of the basics from the placental material. a representative liquid mass. for example. located in a mixed state. ⁇ .e One of the components of the composition has a different physical and chemical characteristics than the well-known foundations. and the use of a targeted supplement of dimethyl sulfide in direct proportion to the components.
  • placental material contained in the placental material. located in a native state. as well as component. possessing a proprietary an ⁇ and mi ⁇ ⁇ practical and analgesic activity.
  • 5 gomeg is divided by a homogeneous structure of the mass with the loss of the line of emergency-specific color with a special reserve.
  • the product is stored and stored in a dry place in the dark when it is in a dry place.
  • the convenience of the components is due to their properties and requirements. Ready for sale.
  • the minimum content of the base and the placental material in the finished product was selected in the amount of 10 wt. % Since, to a lesser extent, her companion is practically not synergistic with the effects of the wounds on the patient, ⁇ .with ⁇ pisisu ⁇ - vyuyut and notable natural phenomena. incidents of this disease. lowering the effectiveness of the components. ⁇ note ⁇ . less than 10% of the base material from the placenta and its content is more than 90% by weight of dimethyl pulse
  • composition of the claimed foundation a liquid-distributing mass of the ilacentric material. having a homogeneous structure and material. present in native ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the one-oil-alcohol emulsion is used in the claimed product as a biologically active substance, which is a matter of a large quantity that is consumable. ⁇ me ⁇ g ⁇ , s ⁇ i ⁇ , s ⁇ de ⁇ zhashiysya in these emulsion 5. is a conservative. and also reveals a partial detrimental effect on certain large protein molecules. that leads to the possibility of recognition of allergic reactions. and the oil constituent emulsion eliminates the danger of tanning from the effects of alcohol. The quick release of biologically active substances into the depths of the tissue.
  • the ratio of the components of the emulsion is 1: 1: 1 convenient for its use. one thing. It may be changed depending on the requirements of the medication on this basis.
  • the one-oil-syrup emulsion is very good and it is well tolerated by patients who have been sent to the well.
  • the resulting system (the regulation of the channel exchange) is subject to an immense amount of inconsequential
  • the product is stored for 20 days when stored in a dry place when it is in a safe place for a short period of time.
  • the minimum content of the base material from the placenta is 25 la in the finished product selected in the amount of 30 wt.%. ⁇ . ⁇ . with a smaller content, the biological activity of the drug is much weaker. The analgesic effect is reduced, and the full benefit of the company is completely free from the effects of the emancipation.
  • the maximum content of the base from the placenta mate- rial in the finished market was selected in the amount of 70 wt.%. t.k ⁇ rp and its larger content, not all biologically active substances are consumed by the consumer;
  • the base is a liquid bulk of the placenta material. located in the current state. obtained from the product. our current bid. It is formed from the placental material ⁇
  • the liquid mass of the placental material is used. It has a homogeneous structure and is located in a mixed kitchen. and its placental material in the net and is 6–10% acetic acid in quantity and up to 10% of the total mass.
  • acetic acid in quantity is designated as a target supplement. Equal or higher than the average quantity of the base.
  • a distinctive, particularly high-quality medicinal product is known to be an unusual combination of a liquid and a large proportion of the placenta. being in a native state. with a target additive - acetic acid. By directing it, I have called upon you to receive medication for internal use. that in the well-known medicinal products on the basis. Obtained from a known semi-manufactured product from a placental material cannot be achieved.
  • the healing of the drug is the creation of the womb Platinum materials. that. for example. There are no words to the effect of the present. Plasma-based materials manufactured by ⁇ ITOGS. This medicament is used for the treatment of various inflammation of the skin.
  • amnestic product is processed by glycerin and the wife is married.
  • the distinctive feature of this device is the recognition of the amnesty in the case of a related and non-compliant property. in the native ⁇ ⁇ 97/48405 ⁇ / 1 ⁇ 96 / 00168
  • a distinctive feature is also the view of the most private medium - a small amnesty unit.
  • the base is mixed with all yel-yyuyu additive is in a liquid state of a structure of a tall liquid. isolated from a liquid placental mass. Good targeted add-on. in the form of a quick charge, it was exchanged for dimethyl sulfide. taken in quantities of more than 1 0% of the mass of the removed material.
  • the distinctive specialty of this medicinal product is the use in the form of a base mixed with a whole additive. isolated from the crushed placental placenta-35 material. located in a native state. as well as its state as a large liquid. On the other hand, the physical and chemical structure in it has been changed. ⁇ .e It is from an amorphous structure that passes through a structure. good ice. in the structure of the heavy liquid with ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • Glycerin is stored inside the internal structures of the material in its neglected state. ⁇ . ⁇ . the high glycerin content prevents the freezing of water from the material and, therefore,
  • the best option for the user is the user interface. at some placental material is in a native ⁇ vc.
  • the industry and processors are in total quantities of up to 10% of the total mass. As a preservative, they use dimethyl sulfoxide or 6-10% acetic acid.
  • the proposed product may be removed from the company; the center of the material of the person. ⁇ ak and from different species of life - us. for example. dog. ⁇ ⁇ disproportionate êt ⁇ ⁇ réelle matters matters matters ⁇ ⁇ ст ст ⁇ ⁇ ст ⁇ ⁇ ст ⁇ ⁇ ⁇ ст ⁇ ⁇ ⁇ -> ⁇ ->
  • the method of preparation is an intensive process described with the largest cultivation. that the placental material is taken away from the living room at home after deliveries and freezing. First and foremost, you have to take advantage of the availability of a public key. toxins and other things. For a good result, the result and the plug-in are considered good.
  • the proposed basic basic medicine is in the hands of the following.
  • the proposed basic medical treatment is available at the end of the next-> next.
  • Dimethyl sulfide supplementation is beneficial in the case of heavy meat or similar machinery. that it is embedded in the placental material in the process of e io and smsii.
  • the resulting mass is achieved by a homogeneous mix of step and / or yellow housing for or with the help of a homogenizer
  • the proposed basic medical equipment may have been obtained from both the human material. such and different species of animals. for example. dog. ⁇ u ⁇ n ⁇ g ⁇ ⁇ ga ⁇ g ⁇ s ⁇ and ( ⁇ vy) and pigs.
  • the placenta of the placenta is excreted. They are immediately absorbed with glycerin and freeze. First and foremost, taking all the necessary requirements for the presence of a pathogen. toxins and other things - to add. at home, the site is in a naive state. After receiving the approval of the quality of the material, it is unloaded. chopping. a good liquid mass. Then, they handle dimethyl sulfide.
  • the proposed base may be used for various types of cooking equipment. At this point, it is extremely important to agree with
  • mice research comparable with similar indicators of a traditional placenta extract.
  • the total cure rate was 2 days.
  • the proposed other basic medicinal product is received by the following method. It takes from a placental material. located in a native state. or ⁇ health- ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the offered equipment may be used for the treatment of various medications with different physical conditions.
  • ⁇ a ⁇ imer ⁇ The previously obtained service is mixed with basic distilled water or with a physiological treatment of sodium chloride. ⁇ ⁇ ⁇ ⁇ ⁇ . on ⁇ nme ⁇ .
  • the private medium does not lose its proprietary analogous property, which is made on a different basis.
  • PRINCIPAL MEDICINAL PRODUCT it is effective to use, as a matter of fact, self-reliant medical equipment for therapeutic operation if there is any other 25 illnesses: ⁇ . Consequences of the treatment of diseases and certain other diseases of the disease, of the engine and the machine. disturbances of exchange of goods. ⁇ c ⁇ iase. for medical and diagnostic purposes and other.
  • ADAPTIVE ACCESSORIES AS SEPARATE TANES. ⁇ a ⁇ and ⁇ organism in the world; improve the ability of organism to self-regulation. All of the aforementioned causes of humanism. in the end ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • the obtained pure mass is obtained from a powder from particles with a simple structure. for example. I grind it at the mill and produce 150 g of powder with natural particles up to 60%.
  • the method of manufacturing a solid base makes it possible to remove mixed mass from a placental material. Protect it with dimesulphoxide, freeze it and freeze dry 35. After that, get used to the clean particles. which, in principle, changes the properties of the fundamentals of the placental material. but it is in the native language of its constructive structure. ⁇ ⁇ 97/48405 ⁇ / _ ⁇ 96 / 00168
  • the mainstay of the medicinal product contains a placenta material in the form of solid particles.
  • Each of the facilities has a built-up structure. ⁇ master ⁇ Result. Each particle is well developed. which allows you to contact her
  • the solid base is made of a placental material with solid particles in the form of a powder.
  • This product has particles with a light and a light bulb.
  • the content of total lipids and ⁇ s ⁇ lipids The highest lipids - 95. 0 mg
  • the proposed base is at 25 level. and in a number of cases there are no problems. for example. right now ⁇ and biological pennies. balance of deliberately active substances. selectivity of processes in the process of distribution and other.
  • the simplest base of medicine is even less likely to be used. for example. in a mixture with a known preparation
  • ⁇ lmagel ' for the manufacture of a medicament. erythematosus and the treatment of gastritis.
  • the proposed medicinal product is squeezed by the convenience of the consumer.
  • Components of the target trust are determined by the prescription of a medication. mass of liquid phase in the main. and also visible and typical vegetable oil.
  • Balloons are assigned to the application of the mediation. content of 20 wt.%: placental material - 38. dimethyl sulfide -62.
  • placental material - 38. dimethyl sulfide -62 After the answer. done in a gypsum. with a putty applied a thin layer of a medium to the area in the area. 30 minutes. then the remainder of the equipment was removed with a tampon. Publications were issued once a day every day for 30 days. Pain was recovered after the 25th application. There was a gradual increase in muscle tissue. Gypsum became tessn. 04/03/93, Gypsum was removed. The previous ns of the city of ⁇ réelle ⁇ ⁇ ane normal. X-rays showed the presence of a by-engine. The pain is not disturbing.
  • placental material - 64 dimethyl sulfide - 36.
  • Another simple remedy for the proposed basic offer is to regulate the exchange of channels. Received in the following way. There is no significant loss of health among women who are pregnant and absenteeism (AIDS, HIV-infection, syphilis). Then it is crushed in a homogenized mass to a mixed mass with a net of 35% of its material. This is the basics. Adds a water-oil-alcohol emulsion. Thoroughly mix and disinfect the glass from the dark glass. Components take in relation to wt% ⁇ ⁇ 97/48405 ⁇ / ⁇ 96 / 00168
  • a one-oil-alcohol emulsion is prepared separately by 5 mixing components. The quicker is ⁇ : 1: 1.
  • ethanol is used as a part of the system. and the quality of the oil is vegetable oil. for example. Cast. For example, 1.
  • the composition is more than 2 months old. How to do it.
  • the claimed medication noted a positive effect on the exchange processes in the external and spinal tissue, which resulted in the loss of treatment. No adverse effect detected.
  • the above one offered medicinal product is prepared by the following method.
  • 6–10% of acetic acid are selected depending on the destination of the drug. mass of liquid phase in the base. It is used both internally and internally. For example. Bolyuy ⁇ . 49 years Diapause - catering. They gave one teaspoon for 0.5 glasses of water for 30 minutes before eating. Once in a day. After the first application - the disappearance of children and children in the epigastria. After a week of treatment, loading with an alcohol did not give the expected feelings.
  • hepatitis. syphilis This is a product. It is short-lived and previously used. Then it is crushed in a homogenizer to a liquid mass. I am processing dimethyl sulfide in quantities of up to 10% of the total mass. The company is in an active state 5th. and the mass has a homogeneous structure. This is one of the latest and most available medications.
  • a medicinal product For the preparation of a medicinal product, it is mixed with a target substance. on a short-term basis, stearic acid or soap is used in quantities and cases. ⁇ creative foamed v ⁇ mass In order to hide its structure, add glycerin in a beneficial way.
  • the base For the manufacture of a medicinal product, it is necessary to remove the base from the amnestic charge of the base and the target allowance. for example. 10% dimethyl sulfide. In this case, the medicament is stored for a long time without the loss of its own medical properties. It is recommended. how in fact - than everything described in this application. in a bank in a cool, dark place. It is used without prior preparation and without
  • Such a medicinal product works as a convenient membrane. creating normal conditions for breathing. in order to stimulate the regeneration of the skin by the complete knowledge of the business and its native structure.
  • the main mixture is mixed with the target additive - dimethyl pulse) in a quantity of 15 over 10% of the total mass. They survive and have room for 7–1 0 days. They then isolate the liquid phase and freeze it. for example. ⁇ Consumer - 10 ° ⁇ . and then - it stops and maintains the temperature of the body fluid. This is a ready-made medication.
  • the following 20 diseases are: arthritis. landfills, investigations of land and buildings and some other diseases of the motor-propulsion device. violations of the exchange of substances. ⁇ vic ⁇ iasis. and also may be used for medical and cosmetic purposes and ⁇ .
  • the proposed inventions are united by a single inventive concept and are provided with their own complete solution.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention se rapporte aux domaines de la médecine, de la cosmétologie et de la médecine vétérinaire, et permet de produire sans générer de déchets des médicaments permettant de soigner certains états. Cette invention permet également d'obtenir un produit semi-fini ainsi que de nombreuses bases dérivées de ce dernier, lesquelles conservent leurs propriétés pendant une longue durée et contiennent un grand nombre de substances biologiques actives à l'état naissant. On connaît déjà, en l'état actuel de la technique, un produit semi-fini permettant d'obtenir des bases de médicaments et contenant des matières placentaires, une base de médicament obtenue à partir de ce produit semi-fini réduit en poudre et se composant de matière placentaire, ainsi qu'un médicament contenant cette base de matière placentaire mélangée à un additif fonctionnel. Cette invention se caractérise par le fait que le produit semi-fini, la base et le médicament contiennent la matière placentaire sous une forme non traditionnelle. La matière placentaire, qui se présente sous forme d'une masse possédant de nouvelles structures, est traitée à l'aide d'additifs qui lui permettent de conserver ses propriétés initiales et/ou de favoriser la pénétration des substances biologiques actives qu'elle contient à travers la peau et dans l'organisme d'une personne ou d'un animal. Cette invention se rapporte également à 11 variantes indépendantes de fabrication du produit semi-fini, ainsi qu'à 4 variantes de production de bases à partir de ce dernier, à 7 variantes de production de médicaments à partir de ces bases, et à 8 variantes de leur développement.
PCT/RU1996/000168 1996-06-21 1996-06-21 Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes WO1997048405A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/RU1996/000168 WO1997048405A1 (fr) 1996-06-21 1996-06-21 Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
AU70030/96A AU7003096A (en) 1996-06-21 1996-06-21 Semi-finished product for producing drug bases, bases obtained using the same and variants, and drugs obtained using these bases and variants

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/RU1996/000168 WO1997048405A1 (fr) 1996-06-21 1996-06-21 Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes

Publications (1)

Publication Number Publication Date
WO1997048405A1 true WO1997048405A1 (fr) 1997-12-24

Family

ID=20130008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1996/000168 WO1997048405A1 (fr) 1996-06-21 1996-06-21 Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes

Country Status (2)

Country Link
AU (1) AU7003096A (fr)
WO (1) WO1997048405A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050047A3 (fr) * 1999-02-22 2000-12-21 Ct De Histoterapia Placentaria Composition pour le traitement du psoriasis
US6858750B2 (en) 2000-01-10 2005-02-22 Fumapharm Ag Use of fumaric acid derivatives for treating mitochondrial diseases
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis
US8821857B2 (en) 2006-10-06 2014-09-02 Anthrogenesis Corporation Human placental collagen compositions and methods of making and using the same
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1061818A1 (ru) * 1982-07-19 1983-12-23 Центральный научно-исследовательский кожно-венерологический институт Способ лечени пустулезного псориаза
SU1169578A1 (ru) * 1984-01-09 1985-07-30 Bezrukov Oleg F Способ консервации амниотической оболочки
EP0246824A2 (fr) * 1986-05-15 1987-11-25 Cell Systems Ltd Cryoprotection biologique
GB2219923A (en) * 1988-06-22 1989-12-28 Inst Kriobiologii I Kriomedits Method for low-temperature preservation of embryos

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1061818A1 (ru) * 1982-07-19 1983-12-23 Центральный научно-исследовательский кожно-венерологический институт Способ лечени пустулезного псориаза
SU1169578A1 (ru) * 1984-01-09 1985-07-30 Bezrukov Oleg F Способ консервации амниотической оболочки
EP0246824A2 (fr) * 1986-05-15 1987-11-25 Cell Systems Ltd Cryoprotection biologique
GB2219923A (en) * 1988-06-22 1989-12-28 Inst Kriobiologii I Kriomedits Method for low-temperature preservation of embryos

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050047A3 (fr) * 1999-02-22 2000-12-21 Ct De Histoterapia Placentaria Composition pour le traitement du psoriasis
US6858750B2 (en) 2000-01-10 2005-02-22 Fumapharm Ag Use of fumaric acid derivatives for treating mitochondrial diseases
US8980832B2 (en) 2003-09-09 2015-03-17 Biogen Idec International Gmbh Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
US8821857B2 (en) 2006-10-06 2014-09-02 Anthrogenesis Corporation Human placental collagen compositions and methods of making and using the same
US8877180B2 (en) 2006-10-06 2014-11-04 Anthrogenesis Corporation Human placental collagen compositions, and methods of making and using the same
US9770488B2 (en) 2006-10-06 2017-09-26 Anthrogenesis Corporation Human placental collagen compositions, and methods of making and using the same
US9775886B2 (en) 2006-10-06 2017-10-03 Celularity, Inc. Human placental collagen compositions, and methods of making and using the same
US9974840B2 (en) 2006-10-06 2018-05-22 Celularity, Inc. Human placental collagen compositions, and methods of making and using the same
US8399514B2 (en) 2007-02-08 2013-03-19 Biogen Idec Ma Inc. Treatment for multiple sclerosis

Also Published As

Publication number Publication date
AU7003096A (en) 1998-01-07

Similar Documents

Publication Publication Date Title
Mujoriya et al. A study on wheat grass and its nutritional value
Johnstone et al. Endocrine system: part 1
WO1990012584A1 (fr) Preparation ayant un action anti-inflammatoire, lactogene et stimulante, et procede pour sa fabrication
WO1997048405A1 (fr) Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
EP0617958A4 (fr) Composition pharmaceutique presentant des actions anti-alcool stimulant le metabolisme de l'energie, stimulant les fonctions de production et de secretion d'acide de la membrane muqueuse de l'estomac, et presentant egalement des actions radioprotectr
US10758578B2 (en) Herbal formulations of carnivorous plants and methods for treating inflammation
WO1995017902A1 (fr) Utilisation d'une souche du champignon fusarium comme producteur de substances et preparation a base celle-ci presentant, des proprietes, adaptogeniques et immunomodulatrices
Osipchuk et al. The use of biologically active substances from plant raw materials in certain physiological conditions of cows
DE60010886T2 (de) Extrakte, formulierung und verwendung von medikamenten aus blättern von cajanus cajan(l.) milsp.
Morse The Detox Miracle Sourcebook: Raw Foods and Herbs for Complete Cellular Regeneration
CN107596355A (zh) 一种医用镇痛、消肿、退热的外用凝胶剂及其制备方法
CN101437489A (zh) 顺势疗法组合物及其试剂盒
CN1240408C (zh) 冻疮防治膏
WO1991000098A1 (fr) Preparation anti-inflammatoire et son procede d'obtention
RU2383350C1 (ru) Средство и способ для очистки кишечника, желчного пузыря и желчных протоков
CN1189301A (zh) 活性花粉膏及其加工方法
RU2156131C1 (ru) Полуфабрикат для получения основы лекарственного средства, основы лекарственного средства из этого полуфабриката (варианты) и лекарственное средство на этой основе (варианты)
WO1995011659A2 (fr) Preparation pharmaceutique a proprietes immunocorrectrices basee sur une suspension cellulaire et procede de traitement du diabete sucre base sur son utilisation
Osipchuk et al. Utilization of Biologically Active Compounds from Plant Materials in Specific Physiological States of Cows
Chan The Dawn of New Medicine: Stem Cell Therapy: Old Dogma, New Hope
Anthis The Complete Book of Essential Oils for Mama and Baby: Safe and Natural Remedies for Pregnancy, Birth, and Children
Zago Cancer Can Be Cured!
CN1712009A (zh) 一种治疗痤疮、青春痘、酒糟鼻、毛囊炎的外用药液
TWI556825B (zh) A variety of natural plant extracts to relieve acid and pain and its preparation method
Moore Principles and Practice of Constitutional Physiology for Herbalists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR BY CA CN GB JP KR KZ MD RU UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 98502751

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载